AstraZeneca Granted FDA Priority Review for Asthma Treatment
08 Juli 2021 - 8:35AM
Dow Jones News
By Jaime Llinares Taboada
AstraZeneca PLC said Thursday that the U.S. Food and Drug
Administration has accepted and granted Priority Review for its
tezepelumab treatment for patients with asthma.
The pharmaceutical company said that tezepelumab is being
developed in collaboration with Amgen Inc. and it is the first and
only biologic to consistently and significantly reduce asthma
exacerbations in a broad population across Phase II and III
clinical trials.
The FDA grants Priority Review to applications for medicines
that offer significant advantages over available options.
Write to Jaime Llinares Taboada at jaime.llinares@wsj.com;
@JaimeLlinaresT
(END) Dow Jones Newswires
July 08, 2021 02:27 ET (06:27 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024